Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of TEV-56286 (emrusolmin) formulations in healthy participants
NCT06911567Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2025
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emrusolmin in multiple system atrophy (MSA) (2 cohorts), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Maximum Observed Drug Concentration at Day 17, Area Under the Drug Concentration-Time Curve from Time 0 to Last Measurable Drug Concentration at Day 17 and 1 more. Started Mar 2025; status: completed.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT06911567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911567.